ArticleHereditas2025
Daidzein and puerarin synergistically suppress gastric cancer proliferation via STAT3/FAK pathway Inhibition.
Article in Hereditas, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The JAK/STAT pathway: a pivotal therapeutic target in disease and advances in natural product modulation.Molecular diversity · 2026Review
- Potential of Dietary Agent Daidzein in Cancer Prevention and Treatment: Opportunities and Challenges.Cancers · 2026Review
- An Integrated Approach Combining Chemical Profiling, Network Pharmacology, and Experimental Validation Is Used to Clarify the Pharmacological Basis of the Yiqi-Tongluo-Huoxue-Mingmu Formula in Diabetic Retinopathy.Journal of diabetes research · 2026Article
- Anticancer Potential of Isoflavones: A Narrative Overview of Mechanistic Insights and Experimental Evidence from the Past Ten Years.Biomedicines · 2025Review
- Nanopuerarin Improves Doxorubicin Therapeutic Efficacy by Inhibiting Angiogenesis via Regulating NSUN2 in Hepatocellular Carcinoma.ACS omega · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer (GC) is the world's health is seriously threatened by a prevalent form of aggressive tumor with a dismal prognosis. The occurrence of gastric cancer poses a concern for public health since it is a malignant tumor with an enhanced incidence and fatality level.
objectiveThe purpose of this study was to determine if the natural drug Daidzein (DZN) and Puerarin (PRN) together effectively suppress the proliferation of GC cells by blocking the STAT3/FAK intervention signalling pathways in BGC-823 cells. MATERIALS AND
methodsFollowing a 24-hour treatment with the combination of DZN and PRN, the cells were examined for a number of assays. The MTT test was used to investigate the cytotoxicity of the DZN + PNR combination. Acridine orange/ethidium bromide (AO/EtBr) dual staining experiments were utilized to investigate apoptotic alterations, and Western blotting and flow cytometry were used to assess the protein expressions of the cell survival, cell cycle, proliferation, and apoptosis proteins.
resultsOur findings showed that, DZN and PRN possessed anticancer properties by blocking the STAT3/FAK signaling cascade. Moreover, we discovered that the DZN and PRN combo reduced the protein levels of STAT3-FAK-dependent targeted genes, such as cyclin-D1, Bcl-2, Bax, MMP-2, prevented the phosphorylation and activation of STAT3, FAK.
conclusionThe current study's findings suggest that the simultaneous administration of DZN and PNR can stop gastric cancer cells from proliferating, trigger apoptosis, and disrupt their cell cycle.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.